



Innovation on Demand: COVID-19 Testing

We have been answering the needs of **in vitro diagnostics around the world for over 80 years**. So, when the pandemic appeared in 2020, we went to work and **delivered a COVID-19 antibody test in just 19 days**. And that was only the beginning.



MAR
2020

March 13, 2020:
WHO declares
COVID-19
a pandemic



APR
2020

IgG

Ortho is first in the world to receive U.S. FDA EUA for its high-throughput COVID-19 antibody test developed in just 19 days. VITROS® Anti-SARS-CoV-2 Total Antibody Test detects the presence of antibodies to the virus in a patient's blood.

Ortho receives second U.S. FDA EUA for its VITROS Anti-SARS-CoV-2 IgG Antibody Test, a serological test that detects the presence of IgG antibodies in a patient's blood sample.



Q4
2020

Ortho develops a high-throughput antigen test to address the need for mass-scale testing and same-day results. The VITROS SARS-CoV-2 Antigen Test can help hospitals and labs reduce testing backlogs, supply shortages and delayed results.



Ortho receives CE mark approval for its VITROS SARS-CoV-2 Antigen Test in Europe

OCT
2020



Ortho receives emergency use approval in India for its VITROS SARS-CoV-2 Antigen Test

JAN
2021

Ortho becomes the first to get U.S. FDA EUA for a high-throughput SARS-CoV-2 antigen test

MAR
2021



Global cumulative deaths exceed **3 million** as deaths soar in the U.S. and western Europe.

APR
2021



Ortho delivers first antibody test in the U.S. to provide numerical values calibrated to the WHO international standard with the VITROS Anti-SARS-CoV-2 IgG Quantitative Antibody Test.

MAY
2021



Ortho receives Health Canada approval for its VITROS SARS-CoV-2 Antigen Test



Ortho helps more than **500,000 patients in India** who require diagnostic testing with the launch of the VITROS Anti-SARS-CoV-2 Total and IgG Assays and their registration for emergency use.

Jun
2021



Global cumulative cases exceed **180 million** and the number of deaths is almost 4 million.



JUL
2021

Ortho receives FDA EUA for VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody Test

Ortho receives U.S. FDA EUA for the VITROS Anti-SARS-CoV-2 Total N Antibody Test, further expanding testing capabilities.

SEP
2021



U.S. surpasses **42 million** infections

REFERENCES:

Statista. Total number of cases and deaths from coronavirus (COVID-19) in the United States as of September 23, 2021. Accessed September 24, 2021. <https://www.statista.com/statistics/1101932/coronavirus-covid19-cases-and-deaths-number-us-americans/>
World Health Organization. COVID-19 weekly epidemiological update. Edition 46. Published June 29, 2021. Accessed September 24, 2021. https://reliefweb.int/sites/reliefweb.int/files/resources/20210629_Weekly_Epi_Update_46.pdf

We won't stop here.

As the conditions surrounding COVID-19 continue to evolve, **we remain dedicated to meeting the testing needs** of clinicians, hospitals and clinical labs through innovative solutions **that support our purpose of saving lives with diagnostics. Because Every Test Is A Life™**